Sally Sansom
DPhil Student
Sally is a DPhil in Population Health candidate within the Health Economics Research Centre (HERC), under the supervision of Professor Sarah Wordsworth, Dr James Buchanan, Dr Padraig Dixon, and Associate Professor Michele Peters.
Sally is passionate about progressing the health economics evidence base required to support the cost-effective translation of genomic diagnostic and therapeutic technologies into routine care.
Through her DPhil, Sally is exploring the valuation of outcomes associated with genome sequencing in economic evaluations. In particular, Sally is seeking to determine which patient- and caregiver-reported instruments are best suited to measuring the outcomes from genome sequencing for rare disease diagnosis in the context of health economic evaluations.
Sally is grateful to have been awarded a full scholarship in support of her studies funded by the Clarendon Fund, Mary Somerville Scholarship and a Department of Population Health Studentship.
She is also a Junior Research Fellow within the Centre for Personalised Medicine (CPM) at the University of Oxford, as well as a Coordinator of the Econ-Omics Special Interest Group within the International Health Economics Association (IHEA), and a member of the Data Access Committee for the Global Angelman Syndrome Registry.
Prior to commencing her DPhil, Sally worked for eight years in roles spanning health economics and strategy consulting, and medical research / clinical trial project management. Sally also holds a Bachelor of Biomedicine (genetics major) from the University of Melbourne, and a Master of Public Health (health economics specialism) from Monash University in Australia.
Recent publications
-
Estimating the impact of Angelman syndrome on parental productivity in Australia using productivity-adjusted life years.
Hartmanis SL. et al, (2023), Disabil Health J, 16
-
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Schattenberg JM. et al, (2021), Liver Int, 41, 1227 - 1242
-
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018.
Morgan A. et al, (2021), Eur J Health Econ, 22, 505 - 518